A single-injection hyaluronic acid (HA) treatment that has proven:

- Greater reduction in knee pain vs. Synvisc-One® (hylan G-F 20)*
- Longer-lasting knee pain relief vs. steroid²
- Clinically equivalent performance to five-injection HA therapy³,⁴

*Some patients were treated with a three-injection Synvisc® regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.
DUROLANE is a single-injection HA designed to deliver powerful, long-lasting knee osteoarthritis (OA) pain relief.¹

Greater reduction in knee pain vs. Synvisc-One (hylan G-F 20)¹

In a Level-1 study, reduction in Visual Analog Scale (VAS) pain scores at 3 and 6 months was significantly greater for DUROLANE compared to Synvisc-One (hylan G-F 20) (p<0.001).¹

Longer-lasting knee pain relief vs. steroid²

In a Level-1 study,

- DUROLANE was proven to be noninferior to steroid at 6 weeks†
- Results favored DUROLANE for WOMAC pain, function and stiffness scores from 12-26 weeks
- Significant reduction in WOMAC pain from baseline with DUROLANE vs. steroid at week 26

*Methylprednisolone acetate (MPA)
†p=0.008 compared to Synvisc-One (hylan G-F 20) baseline

Mean values +/- standard deviation

Steroid DUROLANE

Effect sizes for WOMAC domains with 95% CIs during the blinded phase of the study.
DUROLANE is the only single-injection HA proven to be clinically equivalent to a five-injection therapy. In a Level-1 study, one injection of DUROLANE produced noninferior pain reduction at 6 months to five injections of the comparator HA.

- 79% of patients experienced improved pain control for up to 26 weeks.

Choose convenience without compromise and get powerful results.

93% of DUROLANE patients had a decrease in pain while walking on a flat surface.

DUROLANE significantly improved Quality of Life.

A single injection of DUROLANE significantly improved all KOOS (Knee and Osteoarthritis Outcome Score) parameters in as early as 2 weeks and continued for up to 24 weeks.*
A History of Safe Use

Strong clinical evidence. More clinical studies than any other single-injection HA knee therapy.

During the pivotal trial:
- No serious adverse events were considered related to DUROLANE treatment.
- The most common adverse events were arthralgia (8.6%), injection site pain (2.3%), and joint swelling (1.7%).

DUROLANE is safe for repeated courses of therapy. Repeated use of DUROLANE does not increase the incidence of adverse events.

Significant Reduction in Analgesic Use

<table>
<thead>
<tr>
<th>Mean Values</th>
<th>Weeks 1 - 2</th>
<th>Weeks 3 - 24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesic</td>
<td>0.77 g/wk</td>
<td>0.33 g/wk</td>
</tr>
<tr>
<td>( p )-value</td>
<td>—</td>
<td>( p=0.004 )</td>
</tr>
</tbody>
</table>

DUROLANE patients experienced a significant reduction in analgesic use.
DUROLANE was designed as a single-injection therapy with unique stabilizing technology.**

DUROLANE is a high-molecular-weight, non-avian HA stabilized using a carefully controlled cross-linking process to increase residence time in the knee joint.***

Unlike Synvisc-One

- DUROLANE does not include components of an avian source.**
- DUROLANE was designed as a single-injection therapy.**

Comparison chart**

<table>
<thead>
<tr>
<th></th>
<th>DUROLANE</th>
<th>Synvisc-One</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection Volume</td>
<td>3.0 mL</td>
<td>6.0 mL</td>
</tr>
<tr>
<td>Concentration</td>
<td>2.0% HA</td>
<td>0.8% HA</td>
</tr>
<tr>
<td>HA per Dose</td>
<td>60 mg</td>
<td>48 mg</td>
</tr>
<tr>
<td>HA Source</td>
<td>Biofermentation-derived</td>
<td>Avian-based</td>
</tr>
</tbody>
</table>
Long lasting by design

DUROLANE proved to have an increased residence time in the knee joint:

- A half-life of 4 weeks in the knee joint
- The longest reported half-life of any HA

DUROLANE is the only HA to have residence time measured in humans.

**Terminal half-life of HA injected into the knee**

- DUROLANE (Rabbit)
- DUROLANE (Human)
- Synvisc-One (Rabbit)
- Unmodified High-molecular-weight HA (Rabbit)
Powerful and Long-lasting Pain Relief

A single-injection hyaluronic acid (HA) treatment that has proven:

- Greater reduction in knee pain vs. Synvisc-One (hylan G-F 20)∗
- Longer-lasting knee pain relief vs. steroid2
- Clinically equivalent performance to five-injection HA therapy3,4

∗Some patients were treated with a three-injection Synvisc regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.

Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com, or by contacting Bioventus Customer Service at 1-800-836-4080.